Loading...
Header Logo
Keywords
Last Name
Institution

Sukyung Woo

TitleAssistant Professor
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentPharmaceutical Sciences
Address1110 N Stonewall Ave
Oklahoma City OK 73117-1223
Phone405/271-6593
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Morita Y, Kamal M, Kang SA, Zhang R, Lokesh GL, Thiviyanathan V, Hasan N, Woo S, Zhao D, Leslie M, Suh S, Razaq W, Rui H, Gorenstein DG, Volk DE, Tanaka T. E-selectin Targeting PEGylated-thioaptamer Prevents Breast Cancer Metastases. Mol Ther Nucleic Acids. 2016 Dec 13; 5(12):e399. PMID: 27959340.
      View in: PubMed
    2. Thapa P, Li M, Bio M, Rajaputra P, Nkepang G, Sun Y, Woo S, You Y. Far-Red Light-Activatable Prodrug of Paclitaxel for the Combined Effects of Photodynamic Therapy and Site-Specific Paclitaxel Chemotherapy. J Med Chem. 2016 Apr 14; 59(7):3204-14. PMID: 26974508.
      View in: PubMed
    3. Rajaputra P, Bio M, Nkepang G, Thapa P, Woo S, You Y. Anticancer drug released from near IR-activated prodrug overcomes spatiotemporal limits of singlet oxygen. Bioorg Med Chem. 2016 Apr 01; 24(7):1540-9. PMID: 26928287.
      View in: PubMed
    4. Morita Y, Kamal M, Kang SA, Zhang R, Lokesh GL, Thiviyanathan V, Hasan N, Woo S, Zhao D, Leslie M, Suh S, Razaq W, Rui H, Gorenstein DG, Volk DE, Tanaka T. E-selectin Targeting PEGylated-thioaptamer Prevents Breast Cancer Metastases. Mol Ther Nucleic Acids. 2016; 5:e399. PMID: 28131283.
      View in: PubMed
    5. Devapatla B, Sharma A, Woo S. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer. PLoS One. 2015; 10(9):e0139237. PMID: 26414070; PMCID: PMC4587670.
    6. Sharan S, Woo S. Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities. Front Pharmacol. 2015; 6:33. PMID: 25750626; PMCID: PMC4335258.
    7. Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res. 2012 Apr 01; 18(7):2099-107. PMID: 22307138.
      View in: PubMed
    8. Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, Mould DR, Giaccone G, Yarchoan R, Venitz J, Figg WD. Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol. 2011 Aug; 72(2):294-305. PMID: 21392074; PMCID: PMC3162659.
    9. Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Apr 20; 28(12):2070-6. PMID: 20308663; PMCID: PMC2860408.
    Woo's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _